Implementation of a myasthenia gravis drug‐disease interaction clinical decision support tool reduces prescribing of h igh‐risk medications
Muscle & Nerve · 2023
DOI: 10.1002/mus.27790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2023. Verfasst von Megan E Barra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Medical Order Entry Systems, Decision Support Systems, Clinical, Myasthenia Gravis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Introduction/Aims High‐risk medication exposure is a modifiable risk factor for myasthenic exacerbation and crisis. We evaluated whether real‐time electronic clinical decision support (CDS) was effective in reducing the rate of prescribing potentially high‐risk medications to avoid or use with caution in patients with myasthenia gravis.
Methods
An expert panel reviewed the available drug‐disease pairings and associated severity levels to activate the alerts for CDS. All unique alerts activated in both inpatient and outpatient contexts were analyzed over a two‐year period. Clinical context, alert severity, medication class, and alert action were collected. The primary outcome was alert override rate. Secondary outcomes included the percentage of unique medication exposures avoided and predictors of alert override.
Results
During the analysis period, 2817 unique alerts fired, representing 830 distinct patient‐medication exposures for 577 unique patients. The overall alert override rate was 85% (80.3% for inpatient alerts and 95.8% for outpatient alerts). Of unique medication‐patient exposures, 19% were avoided because of the alert. Assigned alert severity of “contraindicated” were less likely to be overridden (odds ratio [OR] 0.42, 95% confidence interval [CI] 0.32–0.56), as well as alerts activated during evening staffing (OR 0.69, 95% CI 0.55–0.87).
Discussion
Implementation of a myasthenia gravis drug‐disease interaction alert reduced overall patient exposure to potentially harmful medications by approximately 19%. Future optimization includes enhanced provider and pharmacist education. Further refinement of alert logic criteria to optimize medication risk reduction and reduce alert fatigue is warranted to support clinicians in prescribing and reduce electronic health record time burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Neurology, Newton Wellesley Hospital, Newton Lower Falls, Massachusetts, USA.
- Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Megan E Barra, Amanda C Guidon
Zitieren
APA
Barra, M. E., Webb, A. J., Roberts, R. J., Ross, M., Hallisey, R., Szumita, P., & Guidon, A. C. (2023). Implementation of a myasthenia gravis drug‐disease interaction clinical decision support tool reduces prescribing of h igh‐risk medications. Muscle & Nerve. https://doi.org/10.1002/mus.27790
Vancouver
Barra ME, Webb AJ, Roberts RJ, Ross M, Hallisey R, Szumita P, et al. Implementation of a myasthenia gravis drug‐disease interaction clinical decision support tool reduces prescribing of h igh‐risk medications. Muscle & Nerve. 2023. doi:10.1002/mus.27790
BibTeX
@article{Barra2023,
author = {Barra, Megan E and Webb, Andrew J and Roberts, Russel J and Ross, Marjorie and Hallisey, Robert and Szumita, Paul and Guidon, Amanda C},
title = {Implementation of a myasthenia gravis drug‐disease interaction clinical decision support tool reduces prescribing of h igh‐risk medications},
journal = {Muscle & Nerve},
year = {2023},
doi = {10.1002/mus.27790}
}
EUVIMED